Register entry
Seqirus, Inc.
- Registered sites
- 3
- Drug products
- 2
- Live patents
- 0
- Countries
- 3
- Base
- Australia
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingLabellingFinished drug manufacturePackaging
Sites
Facilities
3| Site | Location | Operations | FEI |
|---|---|---|---|
| Seqirus Pty Ltd | ParkvilleAustralia | Analytical testing, Finished drug manufacture | 3002806753 |
| Seqirus Vaccines Limited | LiverpoolUnited Kingdom | Analytical testing, Finished drug manufacture | 3002806949 |
| Seqirus Inc | Holly Springs, NCUnited States | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3007867647 |
Catalogue
Marketed products
2Showing 2 of 2.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| FLUAD | INFLUENZA A VIRUS A/Missouri/11/2025 IVR-279 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/Michigan/105/2025 IVR-285 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/Tokyo/EIS13-175/2025 ANTIGEN (FORMALDEHYDE INACTIVATED) | INJECTION, SUSPENSION | BLA |
| Flucelvax | INFLUENZA A VIRUS A/Tasmania/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Tasmania/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Arizona/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) | INJECTION, SUSPENSION | BLA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.